Clinical

Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients with lymphomas and other cancers.

Patients with Prader-Willi syndrome showed early signs of microvascular disease upon screening.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.

Although B-cell lymphomas can be challenging to study, there have been great advances in treatments in the second-line and later, explained Kami Maddocks, MD, professor of Clinical Internal Medicine, the Ohio State James Comprehensive Cancer Center.

The researchers conducted this study as previous ones have not assessed death rate variations among patients with chronic obstructive pulmonary disease (COPD) across the urban-rural gradient.

A global assessment found that there was a high prevalence of chronic pain in women living with HIV.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.

John L. Marshall M.D., shares insights on health-related quality of life (HRQoL) findings from SUNLIGHT study presented at ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2023.

Committees have worked for the past 4 years to develop uniform definitions of immunotherapy resistance, but they are not yet universally used.

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

A review identified specificities that suggested that infections of respiratory syncytial virus (RSV) evolve chest tomography features.

The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response.

A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.

A panel of medical experts discuss the clinical and financial considerations surrounding the treatment of patients diagnosed with schizophrenia.

Social determinants of health impacting the treatment landscape for schizophrenia are discussed.

Panelists at the American Diabetes Association 83rd Scientific Sessions explained how time in range is emerging as a crucial target in diabetes management.

The FDA approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who had previously been treated based on data from the phase 3 SUNLIGHT trial.

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.

Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

The greatest reduction in skeletal muscle mass was in the lower extremities, a new report shows.

Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.

Coverage of sessions on disparities in access to clinical trials and cancer screening, as well as relationships each to outcomes. A joint session presented by ASCO and the European Society for Medical Oncology (ESMO) highlighted progress and lingering gaps in lung and colorectal screening.

Presentation of the COMMANDS trial offered practice-changing results for luspatercept.

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.